Nuvectis Pharma initiates Phase 1a trial of NXP900 for advanced solid tumors

Nuvectis Pharma, Inc.

Phase 1a dose-escalation study evaluates safety, tolerability, and PK of NXP900 in advanced solid tumor patients.
NXP900 is a novel SRC/YES1 kinase inhibitor with low nanomolar IC50 (YES1: 0.5nM, SRC: 2.4nM).
Preclinical models showed robust single-agent anti-cancer activity across several solid tumor types.
CEO Ron Bentsur highlights NXP900's unique mechanism and target specificity versus multi-kinase inhibitors.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.